RxDoctor Payments Data

Erik Carrasco, MD

Internal Medicine · Miami Lakes, FLNPI 1073762043

Payments from drug & device makers

$560in general payments, 2019–2025

Across 25 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$177
  • Amgen$156
  • CSL Behring$94
  • Pfizer$51
  • Abbott$22
  • Johnson & Johnson$16
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)10$177
Amgen3$156
CSL Behring4$94
Pfizer3$51
Abbott1$22
Johnson & Johnson1$16
Chiesi USA, Inc.1$15
Gilead1$15
Conmed Corporation1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,080
Medicare patients
105
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide43$30,733
JanuviaSitagliptin Phosphate14$12,203
TrulicityDulaglutide13$12,066
JardianceEmpagliflozin13$7,518
SynthroidLevothyroxine Sodium41$4,596
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,469
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,722
Rosuvastatin Calcium120$1,598
Insulin Aspart FlexpenInsulin Aspart14$1,541
Gabapentin87$1,216
Mirtazapine36$980
Oxybutynin Chloride ErOxybutynin Chloride33$968
Albuterol Sulfate HfaAlbuterol Sulfate43$960
Atorvastatin Calcium136$879
Famotidine59$772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Synthroid$177$35,32984 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →